Partial
Partially Aligned
Patient Risk:
Medium
Summary
Most safety and adverse-effect style claims (e.g., myalgia/diarrhea/nausea, rhabdomyolysis, liver dysfunction, fatigue, memory impairment, and linkage of muscle damage to rhabdomyolysis) are generally consistent with the label excerpts provided, and indication/efficacy statements are supported. However, multiple claims are overgeneral or not explicitly supported as written (e.g., constipation and kidney damage/pancreatitis), and the monitoring statement is only partially accurate (timepoint/periodicity language matches label, but wording is generic).
Category Scores
Accurate Statements
Lipitor (atorvastatin) can cause muscle pain or weakness.
Label includes myopathy and rhabdomyolysis warning and myalgia among common adverse reactions.
Lipitor (atorvastatin) can cause nausea.
Nausea is listed among the five most common adverse reactions leading to discontinuation (0.4%).
Lipitor (atorvastatin) can cause diarrhea.
Diarrhea is listed among the five most common adverse reactions leading to discontinuation (0.5%) and among commonly reported adverse reactions.
Lipitor (atorvastatin) can cause fatigue.
Fatigue is listed among adverse reactions.
Lipitor (atorvastatin) can cause rhabdomyolysis.
Label 5.1 notes rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria.
Lipitor (atorvastatin) can cause liver damage.
Label 5.2 describes liver dysfunction and hepatic enzyme/transaminase elevations and lists hepatic failure among adverse reactions; contraindication includes active liver disease.
Monitoring liver function regularly may be recommended to check for liver damage.
Label 5.2 recommends liver function tests prior to and at 12 weeks following initiation and after dose elevation, and periodically thereafter.
Lipitor can cause muscle damage.
Label 5.1 states atorvastatin can occasionally cause myopathy and includes warnings about myopathy/rhabdomyolysis.
Muscle damage from Lipitor can lead to rhabdomyolysis.
Label 5.1 describes rhabdomyolysis (with acute renal failure secondary to myoglobinuria) as part of the skeletal muscle/myopathy risk spectrum.
Reporting side effects to a doctor may lead to dosage adjustment or switching to a different medication.
Label includes dose titration/adjustment (2 Dosage) and warnings to withhold/discontinue in serious myopathy; counseling includes informing healthcare professionals, but does not explicitly state 'switch'—support is indirect via discontinuation/withholding and dose adjustment framework.
Lipitor is effective for lowering cholesterol.
Indications include reducing elevated total-C, LDL-C, apo B, and TG and increasing HDL-C as adjunct to diet.
Lipitor reduces the risk of cardiovascular disease.
Indications include reducing risk of myocardial infarction, stroke, and revascularization/hospitalization/angina depending on population; these are cardiovascular outcomes.
Alternative treatments to Lipitor include Zocor (simvastatin).
Not directly supported by the provided label excerpts; however, label excerpt supports that LIPITOR is a statin class member, and Zocor is another statin. No explicit label text confirming Zocor as an alternative was provided in the excerpts.
Alternative treatments to Lipitor include Crestor (rosuvastatin).
Not directly supported by provided label excerpts; no explicit alternatives list in provided excerpts.
Alternative treatments to Lipitor include Lescol (fluvastatin).
Not directly supported by provided label excerpts; no explicit alternatives list in provided excerpts.
Alternative treatments to Lipitor include Lopid (gemfibrozil).
Not directly supported by provided label excerpts; no explicit alternatives list in provided excerpts.
Alternative treatments to Lipitor include Tricor (fenofibrate).
Not directly supported by provided label excerpts; no explicit alternatives list in provided excerpts.
A doctor may adjust Lipitor dosage or switch to a different medication if necessary after side effects.
Label supports dose adjustment intervals and temporary withholding/discontinuation for serious myopathy; 'switch' not explicitly stated in excerpts.
One should not stop taking Lipitor without consulting a doctor first.
Counseling section advises patients about chronic condition and that therapy components are guided; label excerpts provided do not explicitly state 'do not stop without consulting,' but do support withholding/discontinuation guidance in appropriate clinical circumstances (indirect support).
Unsupported Statements
Lipitor (atorvastatin) can cause abdominal pain.
No abdominal pain is included in the provided label excerpts for adverse reactions.
Lipitor (atorvastatin) can cause constipation.
Constipation is not included in the provided label excerpts.
Lipitor (atorvastatin) can cause kidney damage.
The label excerpt mentions acute renal failure secondary to myoglobinuria in the context of rhabdomyolysis, but does not explicitly state 'kidney damage' as an adverse effect generally.
Lipitor (atorvastatin) can cause pancreatitis.
Pancreatitis is not present in the provided label excerpts.
Lipitor (atorvastatin) can cause memory loss or confusion.
The label excerpt lists 'memory impairment' among adverse reactions but does not support 'confusion' explicitly.
Taking Lipitor in excess of the recommended dosage can increase the risk of side effects.
The provided excerpts state dosage ranges and caution/risks with higher doses in interaction contexts, but do not explicitly claim that exceeding recommended dosage increases risk of side effects.
Contradictions
Important Omissions
Boxed warning content / major contraindication details (e.g., active liver disease, pregnancy/lactation) explicitly tied to patient counseling or risk assessment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims are unsupported as written (abdominal pain/constipation/pancreatitis; generalized 'kidney damage'; 'confusion' not explicitly supported). While many safety statements align with label-listed adverse reactions (myalgia/myopathy, rhabdomyolysis, liver dysfunction, memory impairment), unsupported overgeneralities could mislead assessment of adverse effects. No direct contradictions were identified in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple adverse-effect claims are not supported by the provided prescribing-information excerpts, and some wording is broader than the label (e.g., constipation, pancreatitis, kidney damage, confusion). Monitoring and risk-by-dose statements are also too generic or not explicitly phrased as in the label.
Suggested Improvement
Limit adverse-effect statements to label-listed terms (e.g., myalgia/myopathy, diarrhea, nausea, fatigue, hepatic enzyme/liver failure, rhabdomyolysis, memory impairment) and use label-specific wording for renal involvement (acute renal failure secondary to myoglobinuria) and monitoring (prior to and at 12 weeks after initiation and after dose changes, and periodically). Remove or rephrase unsupported claims.